Targeting Lp(a) in CV risk reduction: where are we now?10' education - Oct. 5, 2022 - Pia Kamstrup, MD, PhD – Copenhagen, Denmark
Video navigation menu
- What is Lp(a)? 00:31
- Three key publications in the Lp(a) field 03:10
- Lp(a)-associated risk is independent of other risk factors 05:11
- High Lp(a) and risk of MI, calcific aortic valve stenosis, HF, ischemic stroke, PAD and mortality 06:34
- Lp(a) levels and incident ASCVD across racial/ethnic subgroup 08:18
- Conclusions 10:22
This lecture by Pia Kamstrup was part of the EBAC-accredited symposium "Lp(a): from causality to therapy" held during the ESC congress 2022.
Pia Kamstrup, MD, PhD is Head of the Department of Clinical Biochemistry at the Copenhagen University Hospital – Herlev & Gentofte, Denmark.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by unrestricted educational grants from NewAmsterdam Pharma, Novartis, Sanofi and Roche Diagnostics.